Test 1

These findings come as many health care professionals still report limited confidence and inconsistent practices regarding RSV immunization discussions.

Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from the week, all in one place.

NVX-CoV2705 is indicated for individuals aged 12 to 64 years with an underlying condition that poses high risk for severe COVID-19 outcomes.

Severe RSV disease in 2022–2023 was most likely to occur in infants under 6 months and older children with pulmonary or neurologic conditions.